Evidence map›Paper›PMID 40733728›Full record

ArticleVaccines2025

Breakthrough Infection After a Primary Series of COVID-19 Vaccination Induces Stronger Humoral Immunity and Equivalent Cellular Immunity to the Spike Protein Compared with Booster Shots.

Yoshifumi Uwamino, Takashi Yokoyama, Yasunori Sato, Shiho Tanaka, Yuka Kamoshita, Ayako Shibata, Toshinobu Kurafuji, Akiko Tanabe, Tomoko Arai, Akemi Ohno and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yoshifumi UwaminoDepartment of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.ORCID 0000-0001-9398-9599
Takashi YokoyamaDepartment of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Yasunori SatoDepartment of Biostatistics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Shiho TanakaDepartment of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Yuka KamoshitaDepartment of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Ayako ShibataDepartment of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Toshinobu KurafujiClinical Laboratory, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Akiko TanabeClinical Laboratory, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Tomoko AraiClinical Laboratory, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Akemi OhnoClinical Laboratory, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Ho NamkoongDepartment of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Tomoyasu NishimuraDepartment of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Masatoshi WakuiDepartment of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.ORCID 0000-0002-3953-0872
Mitsuru MurataDepartment of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Naoki HasegawaDepartment of Infectious Diseases, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.
Hiromichi MatsushitaDepartment of Laboratory Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku 160-8582, Tokyo, Japan.ORCID 0000-0002-1629-6630

Funding

Ishii-Ishibashi Fund for Strategic Partnerships in Medicine and Engineering N/AJapan Agency for Medical Research and Development JP233fa627011, JP21fk0108469, JP23fk0108686Japan Science and Technology Agency JPMJPR22R2Keio Global Research Institute N/AKeio University N/Athe Public Foundation of the Vaccination Research Center N/A
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BNT162b2 vaccinebooster effectbreakthrough infectioncellular immunityhumoral immunityimmune response

Identifiers

PMID40733728
PMCPMC12300087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.